Olema Pharmaceuticals (OLMA) Accumulated Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.2 million, up 202.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 202.06% YoY), and the FY2025 annual result was $8.3 million, up 7335.14% from the prior year.
• Accumulated Expenses retreated to $2.2 million in Q1 2026 per OLMA's latest filing, from $8.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.4 million in Q2 2023 and troughed at $111000.0 in Q4 2024.
• A 5-year average of $2.4 million and a median of $1.1 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 97.97% in 2024, then soared 7335.14% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $296000.0 in 2022, then jumped by 1746.28% to $5.5 million in 2023, then sank by 97.97% to $111000.0 in 2024, then soared by 7335.14% to $8.3 million in 2025, then plunged by 73.32% to $2.2 million in 2026.
• Business Quant data shows OLMA's Accumulated Expenses at $2.2 million in Q1 2026, $8.3 million in Q4 2025, and $406000.0 in Q3 2025.